

**Null Results in Brief****The Fibroblast Growth Factor Receptor Gene  $Arg^{388}$  Allele Is not Associated with Early Lymph Node Metastasis of Breast Cancer****Nikolaus Becker,<sup>1</sup> Alexandra Nieters, and Jenny Chang-Claude**

Deutsches Krebsforschungszentrum, Division of Clinical Epidemiology, 69120 Heidelberg, Germany

**Introduction**

A common observation in clinically detected breast cancers and even in screening-detected cases is that a relevant percentage of tumors small in size ( $\leq 20$  mm) are already nodal positive, *i.e.*, at advanced stage (1). On the other hand, other tumors are still nodal negative, although already relatively large in size. Because metastasis of tumors is not considered to occur at random, exploring underlying mechanisms is crucial for both the understanding of the natural history of the disease and the optimal targeting of screening modalities.

Elevated angiogenesis has been shown to be correlated with increased risk of metastasis and poor prognosis (2). Several polymorphisms in genes coding for angiogenesis and growth factors relevant for angiogenesis have been identified, and some have been found to be related to differences in breast cancer angiogenesis among humans (3).

Recently, a polymorphism in the FGFR4<sup>2</sup> has been identified and shown to be associated with a poor prognosis in breast cancer patients (4). On the basis of specimen of 84 human breast cancer cases and 123 healthy controls, Bange *et al.* (4) obtained the following results: (a) the  $Arg^{388}$  allele was *not* associated with an altered risk of breast cancer; (b) the carriers of the allele experienced a higher risk of early lymph node metastasis compared with wild-type gene carriers which was, however, not statistically significant; and (c) tumor-free survival was significantly reduced among carriers of the allele compared with the wild-type gene carriers. Result (b) was only addressed qualitatively, but based on the data presented in Table 3 of that article, carriers of the  $Arg^{388}$  allele had an OR of 2.2 (95% confidence interval, 0.9–5.3) to develop early lymph node metastasis compared with noncarriers.

**Hypothesis.** We hypothesized that among breast cancer patients with small tumors, the carriers of the  $Arg^{388}$  allele experience a higher risk of lymph node metastasis.

**Materials and Methods**

We used data and specimen of a population-based case-control study on breast cancer carried out in two areas of Germany in

*Table 1* Genotype and nodal status of 246 cases from the German breast cancer case-control study

Genotype <sup>a</sup>	Nodal status				Total	
	Negative		Positive		n	%
	n	%	n	%		
Wild-type	79	42.9	26	41.9	105	42.7
Heterozygous for $Arg^{388}$ allele	88	47.8	28	45.2	116	47.2
Homozygous for $Arg^{388}$ allele	17	9.3	8	12.9	25	10.2
Total	184	100	62	100	246	100

<sup>a</sup>  $P_{\text{Hardy-Weinberg}} = 0.69$ .

1992–1995, including 706 cases and 1381 age-matched controls between the ages of 20 and 52 years [for details see Chang-Claude *et al.* (5)]. For most of the cases, the precise tumor-node-metastasis status was known. From the case series, women having a tumor size  $< 20$  mm at time of diagnosis ( $n = 270$ ) were selected and classified into two groups with respect to nodal involvement. We excluded 24 patients for whom no blood sample ( $n = 6$ ) or no DNA ( $n = 16$ ) was available. For the remaining 266 subjects, the genotype with respect to the FGFR4  $Arg^{388}$  allele was determined with RFLP analysis. For 2 subjects, genotyping did not provide a result, leaving 246 cases for the final analysis (Table 1). Logistic regression (6) was carried out to assess the association, and the Jonckheere-Terpstra test for trend performed using the SAS procedures LOGISTIC and FREQ with the respective trend test option (SAS release 8.2; SAS Institute, Cary, NC). For power calculation, the arcsine approximation was used (6).

**Results**

Among the 246 subjects, 42.7% were homozygous carriers of the wild-type allele. A total of 47.2% was heterozygous, and 10.2% were homozygous carriers of the  $Arg^{388}$  allele (Table 1). Compared with noncarriers,  $Arg^{388}$  allele carriers had an OR of 1.04 (95% CI, 0.6–1.9) for lymph node involvement. The test for trend on the number of mutant alleles provided a  $P$  (one-sided) of  $P_{\text{trend}} = 0.35$ . Inclusion of age into the model did not affect the results.

**Statistical Power, Study Limitations, and Conclusions.** The study has a power of 81% to confirm an odds ratio in the magnitude of OR = 2.2 as found with the data of Bange *et al.* (4) on a one-sided significance level of  $\alpha = 0.05$ . Selection bias may have occurred but is likely to be negligible because of the population-based sampling of the cases and a high degree of ethnic homogeneity of the included cases. We might not have had enough power to detect a weaker association. However, the complete null result observed renders it rather unlikely that insufficient power was the reason that we failed to detect an association. We conclude that the FGFR4  $Arg^{388}$  allele is not associated with increased risk of lymph node metastasis of small breast cancers.

Received 3/7/03; accepted 3/13/03.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> To whom requests for reprints should be addressed, at Deutsches Krebsforschungszentrum, Division of Clinical Epidemiology, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Phone: 49-6221-42-2385; Fax: 49-6221-42-2203; E-mail: n.becker@dkfz.de.

<sup>2</sup> The abbreviations used are: FGFR4, fibroblast growth factor receptor 4; OR, odds ratio.

## Acknowledgments

We thank Ursel Eilber for sampling the data from the breast cancer case-control study and supporting the data analysis, Ina Koegel for genotyping, and Evi Deeg for data management.

## References

1. Evans A. J., Pinder S. E., Burrell H. C., Ellis I. O., and Wilson A. R. M. Detecting which invasive cancers at mammographic screening saves lives? *J. Med. Screen.*, 8: 86–90, 2001.
2. Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R., Janes, L., Velasco, P., Riccardi, L., Alitalo, K., Claffey, K., and Detmar, M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nat. Med.*, 7: 192–198, 2001.
3. Balasubramanian, S. P., Brown, N. J., and Reed, M. W. R. Role of genetic polymorphisms in tumour angiogenesis. *Br. J. Cancer*, 87: 1057–1065, 2002.
4. Bange, J., Prechtel, D., Cheburkin, Y., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., Müller, S., Gärtner, S., Sures, I., Wang, H., Imyanitov, E., Häring H-U., Knayzev, P., Iacobelli, S., Höfler, H., and Ullrich, A. Cancer progression and tumor cell motility are associated with the FGFR4 Arg<sup>388</sup> allele. *Cancer Res.*, 62: 840–847, 2002.
5. Chang-Claude, J., Eby, N., Kiechle, M., Bastert, G., and Becher, H. Breast-feeding and breast cancer risk by age 50 among women in Germany. *Cancer Causes Control*, 11: 687–695, 2000.
6. Breslow, N. E., and Day N. E. *Statistical methods in cancer research, volume II. The design and analysis of cohort studies.* IARC Sci. Publ. No. 82; Lyon, France: IARC, 1987.

# BLOOD CANCER DISCOVERY

## The Fibroblast Growth Factor Receptor Gene *Arg*<sup>388</sup> Allele Is not Associated with Early Lymph Node Metastasis of Breast Cancer

Nikolaus Becker, Alexandra Nieters and Jenny Chang-Claude

*Cancer Epidemiol Biomarkers Prev* 2003;12:582-583.

**Updated version** Access the most recent version of this article at:  
<http://cebp.aacrjournals.org/content/12/6/582>

**Cited articles** This article cites 5 articles, 1 of which you can access for free at:  
<http://cebp.aacrjournals.org/content/12/6/582.full#ref-list-1>

**Citing articles** This article has been cited by 2 HighWire-hosted articles. Access the articles at:  
<http://cebp.aacrjournals.org/content/12/6/582.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cebp.aacrjournals.org/content/12/6/582>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.